Ascendis Pharma Files 6-K, Incorporates by Reference
Ticker: ASND · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1612042
Sentiment: neutral
Topics: filing, registration, corporate-action
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K, incorporating by reference into S-8 filings. Check S-8 numbers 333-203040, 333.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on September 10, 2025, to report information as a foreign private issuer. The filing is related to registration statements on Form S-8, specifically referencing Registration Numbers 333-203040 and 333. The company is incorporated in G7 and its fiscal year ends on December 31.
Why It Matters
This filing indicates Ascendis Pharma is updating or referencing its registration statements, which could be relevant for investors holding or considering stock options or employee stock purchase plans.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not appear to contain new material financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 333-203040 (dollar_amount) — Form S-8 Registration Number
- 333 (dollar_amount) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is filed by Ascendis Pharma A/S as a report of a foreign private issuer and is deemed to be incorporated by reference into its registration statements on Form S-8.
What are the relevant Form S-8 registration numbers mentioned?
The filing specifically mentions Registration Numbers 333-203040 and 333.
When was this Form 6-K filed?
This Form 6-K was filed on September 10, 2025.
Where is Ascendis Pharma A/S's principal executive office located?
The principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports under Form 20-F or 40-F?
Ascendis Pharma A/S indicates it files annual reports under Form 20-F.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2025-09-10 16:04:27
Key Financial Figures
- $202.91 — y and has an exercise price equal to US $202.91 per share, the closing price of the Ame
Filing Documents
- d41121d6k.htm (6-K) — 13KB
- d41121dex11.htm (EX-1.1) — 1204KB
- g41121dsp174.jpg (GRAPHIC) — 3KB
- g41121dsp175.jpg (GRAPHIC) — 3KB
- g41121dsp177.jpg (GRAPHIC) — 3KB
- g41121dsp178.jpg (GRAPHIC) — 3KB
- g41121dsp179.jpg (GRAPHIC) — 3KB
- g41121dsp180.jpg (GRAPHIC) — 5KB
- g41121dsp_24a.jpg (GRAPHIC) — 4KB
- g41121dsp_25a.jpg (GRAPHIC) — 8KB
- g41121dsp_25b.jpg (GRAPHIC) — 3KB
- g41121dsp_26a.jpg (GRAPHIC) — 6KB
- g41121dsp_33a.jpg (GRAPHIC) — 4KB
- g41121dsp_33b.jpg (GRAPHIC) — 8KB
- g41121dsp_34a.jpg (GRAPHIC) — 3KB
- g41121dsp_34b.jpg (GRAPHIC) — 6KB
- g41121page43.jpg (GRAPHIC) — 4KB
- g41121page44a.jpg (GRAPHIC) — 8KB
- g41121page44b.jpg (GRAPHIC) — 3KB
- g41121page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-200073.txt ( ) — 1338KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: September 10, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer